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Abstract 
Purpose: 
To determine the frequency with which Type Il Diabetes 
Mellitus (T2DM) patients managed in a primary care setting 
in the Gozitan community achieved American Diabetes 
Association (ADA) treatment goals for lipids and whether 
this was affected by the degree of glycaemic control. 
Methods: 
A cross-sectional study of 215 randomly selected nDM 
patients treated on a primary care level was conducted. 
Fasting venous blood samples were collected from all 
patients and analysed for HbAlc, FBG, TChol, HDL and 
LDL (Friedewald equation). Patients were subdivided into 
three groups according to glyceamic control: {HbAlc < 7% 
(Good); 7-8% (Satisfactory); >8% (Poor)}. Amongst the 
three glycaemic control groups, differences in mean lipid 
levels were evaluated by one-way analysis of variance 
(ANOVA), and differences in ADA lipid target achievement 
by Chi squared testing. 
Results: 
Amongst the three glycaemic control groups, there were 
Significant differences: in all the mean lipid levels (TChol, 
p<0.004; Tri, p<O.OOI; HDL, p<0.04; LDL, p<0.004 
) and lipid target achievement for Tchol (p<0.03); Tri 
(p<O.OOl); HDL (p<0.05). Frequency of ADA target 
achievements were: HbAlc (33.9%), TChol (58.6%), ill 
(67.9%), HDL(66%), LDL (40%). Frequency of targets at 
goal: (none = 9.3%; 1 = 16.7%; 2 = 29.3%; 3 = 21.4%; 
all 4 = 23 .3%). 
Key Words 
Type 2 Diabetes Mellitus; Glycaemic control; Diabetic 
Dyslipidaemia, American Diabetes Association, Primary Care. 
24 VOLUME 18 ISSUE 01 DECEMBER 2009 
Conclusion: 
Better glycaemic control is associated with a significantly 
better lipid profile for each of the lipid components. The 
magnitude of this association was sufficient to influence 
achievement of all individual ADA lipid goals except that 
for LDL. 
Introduction 
Background 
Gozo forms part of the Maltese Archipelago in the 
Mediterranean Sea. Diabetic rates of the Maltese population 
are amongst the highest in Europe(!) with 10% suffering 
from diabetes as compared to 2-3% of their European 
neighbours. 
Overview of Literature 
Lipid abnormalities affect 70-97% of diabeticsm 
Diabetic dyslipidaemia is characterised by a triad of lipid 
abnormalities including raised Triglycerides (Tri) , low 
High Density Lipoprotein (HDL) and a predominance of 
the highly atherogenic small dense form of Low Density 
Lipoprotein (LDL)m. There is conclusive evidence that 
optimal glycaemic control is central to the management of 
diabetes and the prevention of long-term diabetes-related 
complications, both micro- and macro-vascular disease(4.5) 
Impaired lipid metabolism resulting from uncontrolled 
hyperglycaemia has been implicated in such complications. 
There has not been a study analysing whether the degree 
of glycaemic control has sufficient influence on lipid levels 
to Significantly affect the degree of American Diabetes 
Association (ADA) lipid goal achievement. 
ADA Reco mmended Targets 
To improve diabetic control and prevent diabetic 
complications, the ADA(6) defined the following lipid 
treatment goals for physicians managing patients with 
diabetes mellitus: Total Cholesterol (TCho1) < / =5.2 
mmol!l; LDL </ =2 .6 mmol!l; HDL > 1.1 5 mmolll; Tri 
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< 1. 7 mmol/l; and Haemoglobin Alc (HbAlc) < 7 %. 
The ADA recommended goals were adopted by the 
study as they have been tailored specifically for diabetic 
patients, target all the individual lipid components, and 
already encompass many of the anticipated changes taking 
place within the European guidelines. 
Hypothesis and Study Objectives 
The frequency with which T2DM patients are able to 
attain recommended treatment goals in a primary care 
setting in Gozo remains to be established. Such data is 
especially important to primary care physicians who are 
responsible for providing the bulk of this service. 
In T2DM patients , the state of insulin resistance 
impairs the body's ability to sense glucose in the circulation 
and consequently leads to a compensatory release of free 
fatty acids (FFA) from adipose tissue into the blood 
srream(Y) A high portal FFA concentration has undesirable 
effects on the liver resulting in hepatic insulin resistance 
(lipotoxicity), hyperinsulinaemia, hyperglycaemia and 
dyslipidaemia. 
The results of several studies(s.9.lOl reflect a causal 
link between the degree of glycaemic control as a major 
influence on the level of dyslipidaemia and accelerated 
atherosclerosis as the ultimate end point. It is postulated 
that patients with better glycaemic control have a more 
favourable lipid profile than their counterparts and 
therefore a better chance of achieving ADA recommended 
targets. 
A cross-sectional study was conducted to determine 
the frequency with which patients with T2DM managed 
in a primary care setting in Gozo are achieving ADA 
treatment goals for lipids and to determine whether the 
degree of glycaemic control as measured through HbAlc 
is associated with ADA lipid goal achievement. 
The primary objectives of the study were to 
ascertain: 
1) Whether the serum lipid profile in T2DM patients 
varies significantly amongst the three glyceamic 
control groups. 
2) Whether the three glycaemic control groups have 
significantly different ADA lipid target achievement 
rates . 
3) The frequency of attainment of ADA recommended 
lipid targets by T2DM patients in the sample 
population. 
4) The prevailing patterns of dyslipidaemia in T2DM 
patients living in Gozo. 
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Methodology 
Methods I Procedure 
A cross-sectional study was conducted on 2lS T2DM 
patients attending the Gozo Health Centre and Diabetic 
Outpatient clinic. The study was reviewed and approved 
by the local research ethics committee and patients gave 
informed consent. The participants were randomly selected 
from diabetic registers held at the above institutions using 
a list of computer generated random numbers. Sample size 
was determined by power analysis based on a power value 
of 0.90 and a significance level of 0.05 . 
The inclusion criteria for the study were: 
Patient type: diagnosed as suffering from T2DM as 
defined by the 
WHO (2007) criteria°I). 
• Age: between 20 to 80 years of age 
• Treatment: stabilised on same lipid-lowering therapy 
for ~ 3 months. 
Location: residing in Gozo for the past 12 months. 
Patients pertaining to any of the following criteria were 
excluded: 
Refusing informed consent 
Myocardial infarction, General anaesthesia, or major 
trauma within 12 weeks prior to enrollment 
Pregnant or breast feeding mothers :5 6 months post 
partum 
• Haemolytic disease or significant blood loss 
Renal impairment 
Alcoholism 
On HIV medication, estrogen treatment or taking 
diuretics. 
Recruitment of the participants and data collection took 
place over a 12 week period extending from September 2007 
to November 2007 to avoid major festive activities which 
could have influenced the study results . 
A data input form was completed for each participant 
consisting of 4 main sections: demographic details, medical 
history, clinical parameters and clinical lab results. 
The medical history section consisted of the participant's 
drug history, past medical history and relevant family 
history relating to diabetic/cardiovascular disease in first 
degree relatives. Relevant diabetes-related complications 
were abstracted from the patient's medical record. The 
patient's drug history including diabetic, lipid lowering 
and cardiovascular risk-reduction medications were also 
documented. 
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The clinical parameter section included measurement 
of the patient's blood pressure and body mass index (BMI). 
Measurement techniques were standardised and calibrated 
instruments used. 
Venous blood samples were collected after an overnight 
12-hour fast using a closed vaccutainer technique and 
processed the same day at the Gozo General Hospital. 
The sera were analysed for HbAlc, fasting blood glucose 
(FBG), Tchol, Tri, HDL and LDLCcalculated by Friedewald's 
equation). 
Inter-laboratory and inter-method variability was 
avoided by having all blood samples analysed at the same 
quality controlled lab and using the same equipment. 
The study participants were subdivided into three 
groups according to their degree of glycaemic control as 
indicated by their HbAlc level. A value of < 7% indicated 
good glycaemic control, a value between 7% and 8% 
indicated satisfactory control, and a value >8% indicated 
poor glycaemic control. 
Table I: Overall study results. 
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Statistical Analysis 
The data was evaluated by SPSS v.10 statistical package. 
Missing values were excluded from the analysis . 
Descriptive Statistics 
Descriptive statistics were performed to compute 
means, standard deviations, frequencies , and percentages 
for the demographic variables and for the lipid, blood 
pressure, body mass index, and HbAlc variables. 
Inferential Statistics 
Pearson's correlation test was performed to examine 
various correlations. 
The effect of glycaemic control on the mean of various 
parameters was evaluated by one-way analysis of variance 
(ANOVA). Values of p<O.05 were considered statistically 
significant. 
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Chi squared testing was employed to analyse ADA lipid 
target achievement (nominal binary outcome variables) 
amongst the three glycaemic control groups. 
Results & Data Analysis 
Overall mean results 
The study data are summarized in table 1. A total of 
109 males and 106 females took part in the study with an 
overall mean age of 66 (+/- 10) years ranging between 34 
and 80 years. Overall, study participants were obese with an 
average BMI of30.4kg/m2 ranging from 18.2 to 53.1 kg/m2 
with a mean blood pressure of 13 7/78 mmHg. Glycaemic 
control was found to be narrowly satisfactory with a mean 
(SD) HbA1c of 7.98% (+/-2.00) ranging from 4.5 to 14.4% 
whilst mean (SD) FBGwas 9.8 (+/-3.7) mmol/l. The overall 
mean (SD) lipid levels of all the study participants were 
found to be as follows: TChol5.0mmol/l (+/-2.3) , Tri 1.6 
mmol/l (+/-0.9) , HDL 1.3 mmol/l (+/-0.3) and LDL 3.0 
mmol/l (+/-0.9). 
Fig. 2 - Mealllipid values ill Stratified Glycaemic Groups. 
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Figure 1: Overall attainment of ADA recommended targets. 
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Figure 3: Individual ADA Ilpid Goals achieved by glycaemic control groups 
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The percentage of participants achieving ADA 
recommended targets for HbAlc, Tchol, Tri, HDL and LDL 
are depicted in Fig. l. 
Results after Stratification into three 
Glycaemic Control Groups 
Glycaemic Characteristics 
The three glycaemic control groups were similarly 
matched with regards to age, gender distribution, BMI and 
proportion of patients on lipid lowering treatment. The 
distribution of patients amongst the glycaemic control 
groups was as follows: 34.0% had Good glycaemic control, 
26.5% achieved Satisfactory glycaemic control, and the 
largest percentage 39.5% had Poor glycaemic control. Their 
respective mean HbA1c levels were 6.1 %, 7.5% and 9.9% 
respectively. 
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Mean Lipid Values 
The mean lipid values in the glycaemic control groups 
are depicted in the figure below. The difference in lipid 
levels between the three groups were significant for all of 
the lipoproteins. 
ADA Lipid Target Achievement & 
Lipid Profile Pattern 
The three glycaemic control groups showed different 
degrees of ADA lipid target achievement as demonstrated 
in Fig.3. 
The number and frequency of lipid goals achieved 
amongst the three glycaemic control groups is depicted 
in Fig. 4. 
The good glycaemic control group had the highest 
percentage of patients (31.5%) achieving all four ADA lipid 
targets . The satisfactory glycaemic control group fared 
the worst in ADA lipid target achievement with 15.8% of 
the patients in this group not achieving any of the ADA 
lipid targets. The lipid profile showed that 76.7% of the 
patients had at least one lipid value outside the ADA 
recommended clinical target level whilst 9.3% did not 
succeed in achieving any of the goals. 
The commonest ADA lipid target achievement pattern 
in all three glycaemic control groups is a lipid profile with 
Tri and HDL both at goal. 
Discussion & Interpretation of Results 
HbAlc correlated well with each of the lipid 
components. The magnitude of impaired glycaemic control 
as defined by the three different cutoff values of HbA1c 
was proportionally related with dyslipidaemia in terms of 
significantly higher total cholesterol, triglycerides, and LDL 
levels, and lower HDL levels. This was also reflected in 
ADA lipid goal achievements. Except for LDL, allADA lipid 
goal achievement rates were higher in those with better 
glycaemic control. There was a clear gap between goals 
put forth in guidelines and outcomes achieved in primary 
care(l2). Furthermore, this study gave an unprecedented 
insight into the local scenario of diabetic management 
in the Gozitan community highlighting that LDL goals 
were not adequately being met as compared with other 
European countries. 
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Aim 1: 
Differences in Lipid Profile in Type 2 
Diabetes Mellitus Patients According to 
the Degree of Glycaemic Control 
Glycaemic control was associated with significant 
differences amongst all the lipid components analysed. 
The better the glycaemic control, the better the associated 
mean lipid levels (fig. 2). Pearson's analysis demonstrated 
a highly significant direct correlation between HbAlc and 
each of the individual lipid levels apart from HDL which 
similarly showed a directly inverse correlation. Glycaemic 
control plays an important and significant role in influencing 
dyslipidaemic levels in TlDM patients and can be a 
potentially useful tool to improve all the components of 
diabetic dyslipidaemia. This has practical importance for 
those components for which there is limited pharmacological 
assistance such as HDL and Tri. The methods used to 
achieve glycaemic control can have differential effects on 
lipid levels beyond their effects on glucose metabolism(l3) 
This data expands the clinical applicability of HbAlc not 
only as a reliable biomarker of glycaemic control, but also 
as an indirect indicator of serum lipid profile in TlDM 
patients. Patients with impaired glycaemic control have a 
higher tendency towards having a deranged lipid profile 
and should be thoroughly assessed for dyslipidaemia and 
associated complications(l4) 
Aims2&3: 
Association of Glycaemic Control with Ada 
Lipid Goal Achievement & Frequency of 
Ada Goal Achievement 
Although the magnitude of the effect of glycaemic control 
on lipid profile has been described to be oflimited value by 
some authors, the current study corroborates what Wagner 
et a1. (l5) had concluded from a prospective longitudinal 
intervention study in that glycaemic optimisation is a useful 
tool to improve the components of diabetic dyslipidaemia 
whereby although the effect is individually modest they are 
globally significant. As seen in Fig. 3, the better the degree 
of glycaemic control, the higher the achievement rates of all 
four ADA lipid targets simultaneously (p < 0.05). Similarly, 
with improved glycaemic control, there was a significant 
decrease in the proportion of patients with none of the lipid 
targets at goal (p<O.Ol). When the effect on individual 
lipid target achievement was analysed, better glycaemic 
control was associated with significantly better ADA goal 
achievements for TChol (p<0 .03) and Tri (p<O.OOl). 
The magnitude of this effect appeared to be insufficient to 
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produce a significant increase in HDL and LDLADA target 
achievement. 
As this may have been partially due to the overwhelming 
influence oflipid lowering medications on these parameters, 
patients in the three glycaemic control groups were further 
subdivided into those on and those not on lipid lowering 
treatment and the individual lipid profiles analysed to 
differentiate any pharmacological influence. Chi Squared 
analysis revealed that in the non-lipid treatment sub-groups, 
improved glycaemic control was associated with significant 
differences in HDLgoal achievement (5.9, p<0.05) and Tri 
goal achievement (17.9, p<O.OOl) , but did not influence 
LDL goal achievement (1.4, p>0.05.). 
This may be accounted for due to LDL targets being the 
most stringent and difficult to achieve as well as LDL levels 
are mainly altered qualitatively rather than quantitatively in 
diabetic dyslipidaemia. These results are consistent with 
findings by Erdman et a1. (6) supporting the need for lipid 
modifying agents to be introduced early in the management 
ofTlDM patients with high LDL levels. 
The study revealed that better glycaemic control was 
associated with higher frequencies of ADA lipid goal 
achievement. The commonest lipid pattern affecting TlDM 
patients in the Gozitan community was the achievement of 
two ADA lipid goals (29.3%) with the most frequent lipid 
combination being a combination of Tri and HDL both at 
goal (16.7%). This pattern was most prevalent in the good 
and poor glycaemic control groups. Standard approaches 
to managing diabetes will likely benefit HDL and Tri levels 
even without use of lipid-directed medications. 
AIM 4: 
Overall Results - The Prevailing Patterns 
of Diabetic Dyslipidaemia in Type 2 
Diabetic Patients in Gozo in Comparison 
with other Studies 
The current study portrayed the local diabetic 
dyslipidaemia scenario. Overall, the average lipid levels 
were within recommended ADA lipid targets except for 
LDL. More than 50% of the TlDM patients studied had 
achieved ADA recommended treatment goals for TChol, Tri 
and HDL. 1ii levels had the highest ADA goal achievement 
whilst LDL goal was the most difficult to achieve. Only 
40% of patients managed to achieve the ADA recommended 
treatment goal for LDL. This is low when compared with 
other European countries which had a 51% achievement 
rate according to the EUROASPlRE II study(l7) When 
these values are compared with the proportion of patients 
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reaching glycaemic goal (33.95%), one finds that there 
is a higher proportion of lipid target achievement than 
HbAlc achievement (see Fig. 1). Although only 34% of 
the study patients were within the established ADA target 
for glycaemic control (HbAlc < 7%) , it is comparable to 
international figures. Studies by the American Diabetes 
AssociationOSl, The European Diabetes Policy Group(l9l 
and the Canadian Diabetes Association(20l highlighted 
that over 60% of people with T2DM are still not achieving 
recommended glycaemic goals despite stringent guidelines 
for diabetes management. 
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Limitations of the Study 
Pertains to a single point in time and limited to 
community practice settings. 
Physicians may have been following different 
guideline recommendations. 
Limitations of the Study 
Pertains to a single point in time and limited to 
community practice settings. 
Physicians may have been following different 
guideline recommendations. 
No data on patient compliance and on non-
pharmacological therapies pursued by patients. 
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